LYON, France--(BUSINESS WIRE)--POXEL (Euronext – POXEL - FR0012432516), an independent French biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, announced today its cash position and its turnover for the first half of 2015.
As of June 30th, 2015, the cash and cash equivalents amounted to €29.5 million including the gross proceeds from the Company’s successful IPO in February 2015 raising €26.8 million. The cash and cash equivalents do not include the receipt, effective July 3rd, of the R&D tax credit amounting to €2 million.
As expected, Poxel did not generate revenues during the first half of 2015.
Help employers find you! Check out all the jobs and post your resume.
As of June 30th, 2015, the cash and cash equivalents amounted to €29.5 million including the gross proceeds from the Company’s successful IPO in February 2015 raising €26.8 million. The cash and cash equivalents do not include the receipt, effective July 3rd, of the R&D tax credit amounting to €2 million.
As expected, Poxel did not generate revenues during the first half of 2015.
Help employers find you! Check out all the jobs and post your resume.
